Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 12, Issue 1, 2005, Pages 75-81

  Dagenais, Gilles R ^a   Yi, Qilong ^b   Lonn, Eva ^c   Sleight, Peter ^d   Ostergren, Jan ^e   Yusuf, Salim ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular death; Clinical trials; Myocardial infarction; Smoking; Stroke

Indexed keywords

ALPHA TOCOPHEROL; RAMIPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SMOKING CESSATION; STROKE;

EID: 15244360558     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/00149831-200502000-00012     Document Type: Article

References (21)

1. Becker DM. Clinical approaches to cardiovascular risk factors: smoking. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winston M (editors): Primer in preventive cardiology. American Heart Association; 1994, pp.143-157.
2. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362:847-852.
3. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO, et al. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS investigators. J Am Coll Cardiol 1992; 20:287-294.
4. Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A, et al. Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 2003; 163:2301-2305.
5. Voors AA, van Brussel BL, Plokker HW, Ernst SMPG, Ernst NM, Koomen EM, et al. Smoking and cardiac events after venous coronary bypass surgery. A 15-year follow-up study. Circulation 1996; 93:42-47.
6. Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich P, Wacholder S, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311:1329-1332.
7. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987; 221:253-260.
8. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. Stroke 1994; 25:333-337.
9. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
10. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
11. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the lorsatan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
12. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-22.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-2997.
14. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
15. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
16. Armitage P. Statistical methods in medical research. Oxford: Oxford Blackwell Science, 1971, pp. 184-191.
17. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360:2-3.
18. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease An update. J Am Coll Cardiol 2004; 43:1731-1737.
19. Greenwood DC, Muir KR, Packham CJ, Madeley RJ. Stress, social support and stopping smoking after myocardial infarction in England. J Epidemiol Community Health 1995; 49:583-587.
20. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 1994; 84:1086-1093.
21. Haustein KO. What can we do in secondary prevention of cigarette smoking? Eur J Cardiovasc Prevention Rehab 2003; 10:476-485.